For the potential treatment of idiopathic pulmonary fibrosis (IPF)
Positive topline Phase 2b results announced in December 2024. 
See the press release HERE.
For the potential treatment of idiopathic pulmonary fibrosis (IPF)
Positive topline Phase 2b results announced in December 2024. 
See the press release HERE.
Our programs 1
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
Deupirfenidone
LYT-100
Idiopathic pulmonary fibrosis (IPF)

2

IPF

~120K in US

~110K in EU5


Therapeutic candidate being advanced for the potential treatment of conditions involving inflammation and fibrosis, including idiopathic pulmonary fibrosis (IPF). Also being advanced under the Animal Rule for medical countermeasures; plans underway to study LYT-100 in progressive fibrosing interstitial lung disease (PF-ILDs) as well as other fibrotic conditions where there is human data with pirfenidone suggestive of clinical benefit.

Phase completedPhase in progress
1 We have an active IND on file with the FDA for LYT-100. The FDA and corresponding regulatory authorities will ultimately review our clinical results and determine whether our wholly-owned therapeutic candidates are safe and effective. No regulatory agency has made any such determination that LYT-100 is safe or effective for use by the general public for any indication.

Conditions involving inflammation and fibrosis, including idiopathic pulmonary fibrosis

Deupirfenidone (LYT-100) is currently in development for the treatment of idiopathic pulmonary fibrosis (IPF), which is a rare, progressive and fatal lung disease.  Deupirfenidone is a deuterated form of pirfenidone and is designed to retain the beneficial pharmacology and clinically-validated efficacy of pirfenidone but with a differentiated pharmacokinetic and tolerability profile. Deupirfenidone has demonstrated strong, consistent, and durable efficacy and a favorable tolerability profile in PureTech’s Phase 2b ELEVATE IPF clinical trial. 

Deupirfenidone also has the potential to address multiple underserved diseases, including progressive fibrosing interstitial lung diseases, a group of lung diseases closely related to IPF, as well as other fibrotic conditions where there is human data with pirfenidone suggestive of clinical benefit. 

  • Key Points of Innovation & Differentiation
    • Deupirfenidone slowed lung function decline in patients with IPF as measured by forced vital capacity (FVC) in the Phase 2b ELEVATE IPF trial. It also demonstrated favorable tolerability at both doses studied. The strength of the data to date suggests that deupirfenidone has the potential to serve as a new standard of care.
    • Pirfenidone (Esbriet®) is approved for the treatment of IPF in the US and other countries. Pirfenidone has been shown to slow the decline of lung function and research suggests it extends life by approximately 2.5 years in patients with IPF.1 It is one of two standard-of-care treatments for IPF, with nintedanib (OFEV®) being the other.
  • Program Discovery Process by the PureTech Team
  • Patient Need & Market Potential
  • Milestones Achieved & Development Status
  • Expected Milestones
  • Intellectual Property
1 Fisher, M., Nathan, S. D., Hill, C., Marshall, J., Dejonckheere, F., Thuresson, P., & Maher, T. M. (2017). Predicting Life Expectancy for Pirfenidone in Idiopathic Pulmonary Fibrosis. Journal of Managed Care & Specialty Pharmacy, 23(3-b Suppl), S17 -S24. https://doi.org/10.18553/jmcp.2017.23.3-b.s17.
2 United Kingdom, France, Germany, Italy and Spain.
3 GlobalData Epidemiology and Market Size Search.
4 Dempsey, T., Payne, S. C., Sangaralingham, L. R., Yao, X., Shah, N., & Limper, A. H. (2021). Adoption of the Antifibrotic Medications Pirfenidone and Nintedanib for Patients with Idiopathic Pulmonary Fibrosis. Annals of the American Thoracic Society, 18(7), 1121–1128. https://doi.org/10.1513/annalsats.202007-901oc
Deupirfenidone is currently in development for the treatment of idiopathic pulmonary fibrosis (IPF). IT is a deuterated form of pirfenidone, which is one of the two standard-of-care treatments approved to treat IPF, in addition to nintedanib. Deuteration is intended to make deupirfenidone break down more slowly in the body than pirfenidone. In PureTech’s Phase2b trial, deupirfenidone demonstrated the beneficial pharmacology and clinically-validated efficacy of pirfenidone and the high dose of deupirfenidone demonstrated strong, consistent and durable efficacy with a favorable tolerability profile.

Press Releases